$-0.14 EPS Expected for Sorrento Therapeutics, Inc. (SRNE)

March 15, 2018 - By Graig Alexander

 $ 0.14 EPS Expected for Sorrento Therapeutics, Inc. (SRNE)
Investors sentiment decreased to 0.67 in 2017 Q3. Its down 0.11, from 0.78 in 2017Q2. It is negative, as 9 investors sold Sorrento Therapeutics, Inc. shares while 12 reduced holdings. 3 funds opened positions while 11 raised stakes. 8.31 million shares or 22.78% less from 10.76 million shares in 2017Q2 were reported.
Blackrock Inc reported 667,766 shares. Moreover, Morgan Stanley has 0% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 5,687 shares. California Employees Retirement reported 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). United Kingdom-based Barclays Public Limited Company has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Gofen Glossberg Il stated it has 10,000 shares. Tower Research Cap Ltd Liability Corp (Trc) owns 2,872 shares for 0% of their portfolio. Gagnon Lc invested 0.02% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Citigroup has 0% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 4,000 shares. Meeder Asset Management invested in 1,917 shares. Wells Fargo & Co Mn holds 0% or 2,500 shares. Art Advsr Ltd holds 0.01% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) or 123,455 shares. Creative Planning holds 25,602 shares or 0% of its portfolio. Glenmede Na invested in 0% or 29,135 shares. Vanguard Grp Inc reported 2.18 million shares. Virtu Ltd Liability Corporation holds 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 43,348 shares.

Since January 23, 2018, it had 2 insider buys, and 4 selling transactions for $11.11 million activity. Ng George K had bought 90,000 shares worth $895,500 on Wednesday, February 28. Asia Pacific MedTech (BVI) Ltd had sold 684,288 shares worth $5.18M on Tuesday, January 23. Ji Henry bought $642,770 worth of stock.

Analysts expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report $-0.14 EPS on March, 20.They anticipate $0.30 EPS change or 68.18 % from last quarter’s $-0.44 EPS. The stock increased 0.65% or $0.05 during the last trading session, reaching $7.7. About 1.88M shares traded. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has declined 73.31% since March 15, 2017 and is downtrending. It has underperformed by 90.01% the S&P500.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Ratings Coverage

Among 9 analysts covering Sorrento Therapeutics (NASDAQ:SRNE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sorrento Therapeutics had 27 analyst reports since July 29, 2015 according to SRatingsIntel. On Friday, January 19 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) earned “Buy” rating by Rodman & Renshaw on Monday, December 7. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 7. Oppenheimer maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Thursday, August 10. Oppenheimer has “Buy” rating and $700 target. As per Monday, October 3, the company rating was initiated by TH Capital. The stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) earned “Buy” rating by H.C. Wainwright on Tuesday, June 27. The firm earned “Buy” rating on Thursday, March 1 by Oppenheimer. The rating was maintained by Brean Capital with “Buy” on Wednesday, July 29. On Tuesday, August 29 the stock rating was maintained by Oppenheimer with “Buy”. The firm has “Buy” rating given on Thursday, June 15 by FBR Capital.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $636.74 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It currently has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.

More notable recent Sorrento Therapeutics, Inc. (NASDAQ:SRNE) news were published by: Globenewswire.com which released: “Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver …” on March 05, 2018, also Seekingalpha.com with their article: “Sorrento Therapeutics: Explicating The New Data Finding” published on March 06, 2018, Globenewswire.com published: “Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non …” on February 28, 2018. More interesting news about Sorrento Therapeutics, Inc. (NASDAQ:SRNE) were released by: Globenewswire.com and their article: “Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th …” published on March 08, 2018 as well as Seekingalpha.com‘s news article titled: “Sorrento Therapeutics: Insider Buying Alert” with publication date: March 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.